Cargando…
Copper–zinc superoxide dismutase-mediated redox regulation of bortezomib resistance in multiple myeloma
Multiple myeloma (MM) is an incurable B-cell malignancy. The proteasome inhibitor bortezomib (BTZ) is a frontline MM drug; however, intrinsic or acquired resistance to BTZ remains a clinical hurdle. As BTZ induces oxidative stress in MM cells, we queried if altered redox homeostasis promotes BTZ res...
Autores principales: | Salem, Kelley, McCormick, Michael L., Wendlandt, Erik, Zhan, Fenghuang, Goel, Apollina |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4309843/ https://www.ncbi.nlm.nih.gov/pubmed/25485927 http://dx.doi.org/10.1016/j.redox.2014.11.002 |
Ejemplares similares
-
Interleukin-6 counteracts therapy-induced cellular oxidative stress in multiple myeloma by up-regulating manganese superoxide dismutase
por: Brown, Charles O., et al.
Publicado: (2012) -
Copper/Zinc-Superoxide Dismutase in Human Epidermis: An Immunochemical Study
por: Altobelli, Giovanna G., et al.
Publicado: (2019) -
Copper/Zinc Superoxide Dismutase in Human Skin: Current Knowledge
por: Altobelli, Giovanna G., et al.
Publicado: (2020) -
Bacterial Evolutionary Precursors of Eukaryotic Copper–Zinc Superoxide Dismutases
por: Wright, Gareth S A
Publicado: (2021) -
Changes in Expression of Manganese Superoxide Dismutase, Copper and Zinc Superoxide Dismutase and Catalase in Brachionus calyciflorus during the Aging Process
por: Yang, Jianghua, et al.
Publicado: (2013)